Loading clinical trials...

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects | Clinical Trials | Clareo Health

COMPLETEDPHASE1

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

An Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

NCT07027982•Dong-A ST Co., Ltd.

View on ClinicalTrials.gov

Summary

This study will evaluate the pharmacokinetics and safety of Diluted and Undiluted Intravenous DA-5217 in healthy adult subjects.

Eligibility

Age

19 - 45 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy adult male or female, 19 years to 45 years
•Weighing 50 kg or more, with a body mass index (BMI) of 18.5 kg/m2 to 29.9kg/m2
•The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate and complied with the precautions.

Exclusion Criteria

•The subjects with existing or previous conditions that may influence the pharmacokinetics of drugs
•The subjects hypersensitive to any of the Investigational Product components or other drug components
•The subjects with clinically significant active chronic conditions
•The subjects with a positive urine drug test result or a history of drug abuse or dependence.
•The subjects who are pregnant or lactating

Locations (1)

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Key Dates

Start Date

July 16, 2025

Primary Completion Date

August 14, 2025

Completion Date

August 14, 2025

Last Updated

August 22, 2025

Enrollment

ACTUAL participants

Conditions

Healthy Adults

Interventions

Diluted Intravenous DA-5217

DRUG

Undiluted Intravenous DA-5217

DRUG

Health Properties of Pecan Nut Consumption

NCT07227259

Healthy Adults

View study

RECRUITINGPHASE1

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

NCT06815991

Healthy Adults

View study

RECRUITING

CanCan Body Composition Study

NCT07305753

Healthy Participants

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 22, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study to Evaluate the Pharmacokinetics and Safety of Diluted vs. Undiluted Intravenous DA-5217 in Healthy Adult Subjects

Inclusion Criteria

Exclusion Criteria

Health Properties of Pecan Nut Consumption

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

CanCan Body Composition Study

Normative Data for Cardiorespiratory Fitness in Healthy Adults

Use of Stable Carbon And Nitrogen Isotopes to Improve Dietary Assessment for Cardiovascular Disease

Transitions and Old Age Potential - 1st, 2nd, and 3rd Wave